BR112023003010A2 - Método de fracionamento de plasma humano, composição, e, preparações de um fator de coagulação, de igg, de um membro selecionado de a1pi, at-iii e uma combinação dos mesmos e de albumina - Google Patents

Método de fracionamento de plasma humano, composição, e, preparações de um fator de coagulação, de igg, de um membro selecionado de a1pi, at-iii e uma combinação dos mesmos e de albumina

Info

Publication number
BR112023003010A2
BR112023003010A2 BR112023003010A BR112023003010A BR112023003010A2 BR 112023003010 A2 BR112023003010 A2 BR 112023003010A2 BR 112023003010 A BR112023003010 A BR 112023003010A BR 112023003010 A BR112023003010 A BR 112023003010A BR 112023003010 A2 BR112023003010 A2 BR 112023003010A2
Authority
BR
Brazil
Prior art keywords
human plasma
a1pi
igg
albumin
preparations
Prior art date
Application number
BR112023003010A
Other languages
English (en)
Inventor
Patatanyan Zhorzh
Murthy Rohit
Baddour Yasser
Zaydenberg Alexander
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of BR112023003010A2 publication Critical patent/BR112023003010A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/145—Extraction; Separation; Purification by extraction or solubilisation
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D1/00—Evaporating
    • B01D1/14—Evaporating with heated gases or vapours or liquids in contact with the liquid
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D1/00—Evaporating
    • B01D1/16—Evaporating by spraying
    • B01D1/18—Evaporating by spraying to obtain dry solids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8121—Serpins
    • C07K14/8125—Alpha-1-antitrypsin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/16—Blood plasma; Blood serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8121—Serpins
    • C07K14/8128—Antithrombin III

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Analytical Chemistry (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

MÉTODO DE FRACIONAMENTO DE PLASMA HUMANO, COMPOSIÇÃO, E, PREPARAÇÕES DE UM FATOR DE COAGULAÇÃO, DE IGG, DE UM MEMBRO SELECIONADO DE A1PI, AT-III E UMA COMBINAÇÃO DOS MESMOS E DE ALBUMINA. A presente invenção fornece um método de fracionamento de plasma humano, em algumas modalidades, usando o procedimento de fracionamento de Cohn. A melhoria compreende o uso de plasma humano seco por pulverização reconstituído fisiologicamente ativo como material de partida para o procedimento de fracionamento.
BR112023003010A 2020-10-01 2021-10-01 Método de fracionamento de plasma humano, composição, e, preparações de um fator de coagulação, de igg, de um membro selecionado de a1pi, at-iii e uma combinação dos mesmos e de albumina BR112023003010A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063086335P 2020-10-01 2020-10-01
PCT/IB2021/000680 WO2022069945A1 (en) 2020-10-01 2021-10-01 Plasma fractionation process utilizing spray-dried human plasma

Publications (1)

Publication Number Publication Date
BR112023003010A2 true BR112023003010A2 (pt) 2023-04-04

Family

ID=79170928

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023003010A BR112023003010A2 (pt) 2020-10-01 2021-10-01 Método de fracionamento de plasma humano, composição, e, preparações de um fator de coagulação, de igg, de um membro selecionado de a1pi, at-iii e uma combinação dos mesmos e de albumina

Country Status (12)

Country Link
US (1) US20220106357A1 (pt)
EP (1) EP4222161A1 (pt)
JP (1) JP2023545948A (pt)
KR (1) KR20230078629A (pt)
CN (1) CN116096385A (pt)
AU (1) AU2021354979A1 (pt)
BR (1) BR112023003010A2 (pt)
CA (1) CA3189976A1 (pt)
CO (1) CO2023001489A2 (pt)
IL (1) IL300384A (pt)
MX (1) MX2023003483A (pt)
WO (1) WO2022069945A1 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9561184B2 (en) 2014-09-19 2017-02-07 Velico Medical, Inc. Methods and systems for multi-stage drying of plasma
US11841189B1 (en) * 2022-09-15 2023-12-12 Velico Medical, Inc. Disposable for a spray drying system
US11975274B2 (en) 2022-09-15 2024-05-07 Velico Medical, Inc. Blood plasma product

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8407912B2 (en) * 2010-09-16 2013-04-02 Velico Medical, Inc. Spray dried human plasma
AU2010202125B1 (en) * 2010-05-26 2010-09-02 Takeda Pharmaceutical Company Limited A method to produce an immunoglobulin preparation with improved yield
US20140083627A1 (en) * 2012-09-27 2014-03-27 Velico Medical, Inc. Automated spray drier

Also Published As

Publication number Publication date
CA3189976A1 (en) 2022-04-07
US20220106357A1 (en) 2022-04-07
EP4222161A1 (en) 2023-08-09
CO2023001489A2 (es) 2023-02-16
IL300384A (en) 2023-04-01
MX2023003483A (es) 2023-04-14
AU2021354979A1 (en) 2023-02-23
WO2022069945A1 (en) 2022-04-07
CN116096385A (zh) 2023-05-09
KR20230078629A (ko) 2023-06-02
JP2023545948A (ja) 2023-11-01

Similar Documents

Publication Publication Date Title
BR112023003010A2 (pt) Método de fracionamento de plasma humano, composição, e, preparações de um fator de coagulação, de igg, de um membro selecionado de a1pi, at-iii e uma combinação dos mesmos e de albumina
CY1124019T1 (el) Σταθεροποιημενη διαλυτη πρωτεϊνη προσυντηξης rsv f για χρηση στην προφυλαξη απο λοιμωξη rsv
AU2018338314A1 (en) Protein degraders and uses thereof
CY1117387T1 (el) ΜΟΝΟΚΛΩΝΙΚΑ ΑΝΤΙΣΩΜΑΤΑ Ν-11 ΔΙΑΣΠΑΣΜΕΝΟΥ β-ΑΜΥΛΟΕΙΔΟΥΣ, ΣΥΝΘΕΣΕΙΣ, ΜΕΘΟΔΟΙ ΚΑΙ ΧΡΗΣΕΙΣ
CL2021002242A1 (es) Proteínas de unión condicionalmente activadas restringidas (divisional de la solicitud no. 202000570)
MX2020011257A (es) Ácidos nucleicos recombinantes que codifican una o más proteínas cosméticas para usos estéticos.
CY1119198T1 (el) ΣΤΑΘΕΡΗ ΣΥΝΘΕΣΗ ΠΟΥ ΠΕΡΙΛΑΜΒΑΝΕΙ PTHrP ΚΑΙ ΧΡΗΣΕΙΣ ΑΥΤΗΣ
NO20053920L (no) Preparat for og behandling av demyelineringssykdommer og paralyse ved administrering av remyelineringsmidler.
CO6400235A2 (es) Tensiactivos reconstituidos que tienen propiedades mejoradas
CY1118930T1 (el) Ανασυνδυασμενες πρωτεϊνες ελαστασης και μεθοδοι βιομηχανικης κατασκευης και χρηση αυτων
PE20211469A1 (es) Proteinas f de prefusion del vrs estabilizadas
WO2020132658A3 (en) Tubulysins and protein-tubulysin conjugates
WO2020172482A3 (en) Cd80 extracellular domain-fc fusion proteins for treating pd-l1 negative tumors
MX2022000713A (es) Derivados de bencenosulfonamida y usos de las mismas.
BRPI0412441A (pt) método para estabilizar um crioprecipitado de proteìnas plasmáticas para ser submetido a um tratamento térmico de inativação viral
BR112021018608A2 (pt) Anticorpos para claudina-6 e conjugados de fármaco
CY1124964T1 (el) Τοπικη συνθεση για την θεραπευτικη αντιμετωπιση δερματικων διαταραχων συμπεριλαμβανομενης της ανδρικης τριχοπτωσης
CO2023017358A2 (es) Formulaciones de proteínas quiméricas del factor viii y usos de las mismas
CO2020016008A2 (es) Formulación de proteína de fusión estable
CO2023011853A2 (es) Anticuerpos anti-variable delta 1 de tcr
MX2022002842A (es) Composiciones y metodos para el tratamiento del virus sincitial respiratorio.
Li et al. Egg White peptide KPHAEVVLR promotes skin fibroblasts migration and mice skin wound healing by stimulating cell membrane Hsp90α secretion
CL2022003715A1 (es) Tubulisinas y conjugados de proteinas-tubulisina
WO2018004294A3 (ko) 인간 성장호르몬 변이 단백질 또는 이의 트랜스페린 융합 단백질을 유효성분으로 포함하는 약학적 조성물
BR112023002089A2 (pt) Compostos de piridazina 6-substituídos como degradadores de smarca2 e/ou smarca4